This result suggests that the synergistic effect of PI3K pathway inhibitor BYL719 combined with radiotherapy in the treatment of cervical cancer is better than that of mTOR inhibitor EVE, which is a significant finding for improving the radiosensitivity of cervical cancer (26). Here, PIK3CG is linked to cervical carcinoma.